Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that the candin antifungal agent, "Funguard® for Infusion" (generic name: micafungin...
Tokyo, Japan April 17, 2006 - Astellas Pharma Inc. (President and CEO: Toichi Takenaka, "Astellas") today announced that the total consideration for the sale of all outstanding shares of Zepharma...
Japan, April 13, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that its EU subsidiary submitted a Marketing Authorization...
Astellas Pharma Inc.("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) announced that Astellas today established a new active pharmaceutical ingredient (API) manufacturing...
Follow us
